Literature DB >> 11003352

Economic cost of expanded criteria donors in cadaveric renal transplantation: analysis of Medicare payments.

J F Whiting1, R S Woodward, E Y Zavala, D S Cohen, J E Martin, G G Singer, J A Lowell, M R First, D C Brennan, M A Schnitzler.   

Abstract

BACKGROUND: The use of expanded criteria donors (ECDs) in cadaveric renal transplantation is increasing in the US. We assess the economic impact of the use of ECDs to the Medicare end stage renal disease program.
METHODS: The United Nations for Organ Sharing renal transplant registry was merged to Medicare claims data for 42,868 cadaveric renal transplants performed between 1991-1996 using USRDS identifiers. Only recipients for whom Medicare was the primary payer were considered, leaving 34,534 transplants. An ECD was defined as (1) age < or =5 or > or =55 years, (2) nonheart-beating donors, donor history of (3) hypertension or (4) diabetes. High-risk recipients (HRR) were age >60 years, or a retransplant. Medicare payments from the pretransplant dialysis period were projected forward to provide a financial "breakeven point" with transplantation.
RESULTS: There were 25,600 non-HRR transplants, with 5,718 (22%) using ECDs, and 8,934 HRR transplants, of which 2,200 (25%) used ECDs. The 5-year present value of payments for non-ECD/non-HRR donor/recipient pairings was $121,698 vs. $143,329 for ECD/non-HRR pairings (P<0.0001) and, similarly was $134,185 for non-ECD/HRR pairings vs. $165,716 for ECD/HRR pairings (P<0.0001). The break even point with hemodialysis ranged from 4.4 years for non-ECD/ non-HRR pairings to 13 years for the ECD/HRR combinations but was sensitive to small changes in graft survival. Transplantation was always less expensive than hemodialysis in the long run.
CONCLUSIONS: The impact of ECDs on Medicare payments is most pronounced in high-risk recipients. Cadaveric renal transplantation is a cost-saving treatment strategy for the Medicare ESRD program regardless of recipient risk status or the use of ECDs.

Entities:  

Mesh:

Year:  2000        PMID: 11003352     DOI: 10.1097/00007890-200009150-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  Intermediate-term outcomes with expanded criteria deceased donors in kidney transplantation: a spectrum or specter of quality?

Authors:  Robert J Stratta; Michael S Rohr; Aimee K Sundberg; Alan C Farney; Erica L Hartmann; Phillip S Moore; Jeffrey Rogers; Samy S Iskandar; Michael D Gautreaux; David F Kiger; William Doares; Teresa K Anderson; Gloria Hairston; Patricia L Adams
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  Compensated living kidney donation: a plea for pragmatism.

Authors:  Faisal Omar; Gunnar Tufveson; Stellan Welin
Journal:  Health Care Anal       Date:  2009-01-29

3.  Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients.

Authors:  Krista L Lentine; Mark A Schnitzler; Kevin C Abbott; Kosha Bramesfeld; Paula M Buchanan; Daniel C Brennan
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

4.  The economic impact of addressing the organ shortage with clinically high-risk allografts.

Authors:  Krista L Lentine; Mark A Schnitzler
Journal:  Mo Med       Date:  2011 Jul-Aug

5.  Increased kidney transplantation utilizing expanded criteria deceased organ donors with results comparable to standard criteria donor transplant.

Authors:  Robert J Stratta; Michael S Rohr; Aimee K Sundberg; Greg Armstrong; Gloria Hairston; Erica Hartmann; Alan C Farney; Julie Roskopf; Samy S Iskandar; Patricia L Adams
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

6.  In defense of the reverence of all life: Heideggerean dissolution of the ethical challenges of organ donation after circulatory determination of death.

Authors:  D J Isch
Journal:  Med Health Care Philos       Date:  2007-05-02

7.  Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure.

Authors:  Krista L Lentine; Lisa A Rocca Rey; Swathy Kolli; Giuliana Bacchi; Mark A Schnitzler; Kevin C Abbott; Huiling Xiao; Daniel C Brennan
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

8.  The Changing Financial Landscape of Renal Transplant Practice: A National Cohort Analysis.

Authors:  D A Axelrod; M A Schnitzler; H Xiao; A S Naik; D L Segev; V R Dharnidharka; D C Brennan; K L Lentine
Journal:  Am J Transplant       Date:  2016-10-04       Impact factor: 8.086

9.  Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice.

Authors:  Vikas R Dharnidharka; Abhijit S Naik; David Axelrod; Mark A Schnitzler; Huiling Xiao; Daniel C Brennan; Dorry L Segev; Henry Randall; Jiajing Chen; Bertram Kasiske; Krista L Lentine
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

10.  Novel methods for tracking long-term maintenance immunosuppression regimens.

Authors:  Paula M Buchanan; Mark A Schnitzler; Daniel C Brennan; Nino Dzebisashvili; Lisa M Willoughby; David Axelrod; Paolo R Salvalaggio; Kevin C Abbott; Thomas E Burroughs; Krista L Lentine
Journal:  Clin J Am Soc Nephrol       Date:  2007-12-12       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.